This article argues against the treatment of Attention deficit/hyperactivity disorder (ADHD) with stimulant medication and behavior therapy, which are also typically reimbursed by healthcare insurers. Evidence suggests that these treatments fail to result in sustained benefit for the vast majority of children who receive them as demonstrated in the NIMH-funded MTA Cooperative study, the gold standard study in ADHD treatment effectiveness research. The authors instead look at the use of neurofeedback which is uniquely suited to treat the neuronal dysregulation that is common in people diagnosed with ADHD. However, healthcare insurers do not regularly cover this treatment method, so the authors direct readers to resources to appeal insurers' denial of coverage for neurofeedback.